The present disclosure generally relates to systems and methods for detecting, predicting or logging seizures in a human patient and, optionally, providing a therapy in response thereto. More particularly, the present disclosure relates to a system and methods for detecting physiological changes indicative of a seizure in a patient having an implanted seizure control device, and using coordinate data, such as GPS, to improve seizure detection algorithm specificity.
Implantable devices have been developed for delivering targeted nervous stimulation at preprogrammed intervals as a therapy for neurological disorders, such as epileptic seizures. It has been shown that measurable parameters of cardiac activity correlate with epileptic seizure events. Consequently, methods have been developed for recognizing a seizure event by measuring changes in heart rate. One challenge to this methodology is that many reasons exist that can cause a heart rate change, such as physical exertion. Thus, heart rate changes alone can give a misleading indication of a seizure event if the heart rate changes are precipitated by other causes. The present disclosure is directed to overcoming, or at least reducing the effects, of one or more of the issues set forth above.
It has been recognized that it would be desirable to discriminate heart rate changes associated with a seizure from heart rate changes precipitated by other causes, when determining whether to trigger nervous stimulation for seizure control.
It has also been recognized that information regarding activity or location or position of an individual can help distinguish heart rate changes that accompany a seizure from those that relate to other causes.
In accordance with one aspect thereof, the present disclosure provides a seizure detection device, including a coordinate data interface configured to receive coordinate data for a human, a memory to store coordinate data for a defined location where the human has previously been, and a seizure detector configured to identify a seizure event responsive to the coordinate data.
In accordance with another aspect thereof, the present disclosure provides a system for nerve stimulation, including a pulse generator device suitable for subcutaneous implantation into a human body, and a coordinate data interface configured to receive coordinate data for the human body. A memory is also provided to store coordinate data for a defined location where the human has previously been, and an activation device is configured to activate the pulse generation device responsive to the coordinate data.
In accordance with yet another aspect thereof, the disclosure provides a method for detecting seizures, including the steps of receiving coordinate data for a human body, determining a seizure threshold responsive to the coordinate data, and identifying a seizure event responsive to the seizure threshold.
These and other embodiments of the present application will be discussed more fully in the description. The features, functions, and advantages can be achieved independently in various embodiments of the claimed invention, or may be combined in yet other embodiments.
While the disclosure is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope as defined by the appended claims.
Illustrative embodiments are described below as they might be employed in a system for seizure detection using coordinate data. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Further aspects and advantages of the various embodiments will become apparent from consideration of the following description and drawings. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that modifications to the various disclosed embodiments may be made, and other embodiments may be utilized, without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense.
As used herein, the term “implantable” means a device that can be completely implanted into a human or animal body, with no portions of the apparatus extending outside the body after implantation.
As used herein, the terms “implantable device” and “implantable medical device” or “IMD” mean any type of electrical device that is implantable into a human or animal body, and is configured to monitor or affect a function of the body. Examples of implantable medical devices include cardiac pacemakers, nerve stimulation devices, and implantable drug delivery devices.
There are a variety of implantable devices that can be used for monitoring and affecting physiological or biological function of a human body. Such devices include cardiac pacemakers, implantable drug delivery systems and nerve stimulation devices. Among the latter are implantable devices for nerve stimulation, such as vagus nerve stimulation (VNS). VNS was approved by the FDA in 1998 as an adjunctive therapy for epilepsy with partial onset seizures. VNS is achieved through an implanted pulse generator that delivers a bipolar, biphasic pulse to the vagus nerve. The implant procedure is very similar to the implantation of a pacemaker. The generator is implanted subcutaneously, typically in the upper left pectoral region. An electric lead is connected between the pulse generator and one or more electrodes that are attached to the vagus nerve.
Shown in
The implantable VNS system 10 can also include an antenna 24, a GPS receiver 26, and a microprocessor 28 with digital memory 30. These elements can be included within the housing of the pulse generation device 14. It will be appreciated by those of skill in the art that the pulse generation device can also include other elements that are not shown in
The pulse generator 14 can be a multi-programmable device, which allows a physician to set various parameters of operation of the device. The programmable parameters can include signal amplitude (e.g., 0-3.5 mA), frequency (e.g., 1-30 Hz), pulse width (e.g., 130-1000 μs), signal ON time (e.g., 7-60 sec) and signal OFF time (e.g., 0.2-180 min). It is to be appreciated that these pulse parameters are only exemplary, and that other parameters can also be used. The pulses can be delivered at the specified amplitude and frequency over the course of the ON time, and then during the OFF time, no stimulation takes place. This type of device typically does not stimulate continuously because it has been found that the antiepileptic effect tends to last much longer than the actual time of stimulation. In one embodiment, pulse settings can be 2 mA, at 15 Hz frequency, 250 μs pulse width, with a 30 sec ON time, and 5 min OFF time. The variability in parameters allows the physician to adjust for greater efficacy or less severe side effects, depending on the patient.
The implantable nerve stimulation device can also include programming and structure to allow adjustment of its operation in real-time based upon detected physiological conditions of the patient in whom it is implanted. Of particular interest in this disclosure, a seizure detector can be provided in conjunction with an implanted device, such as the pulse generation device 14, to identify a seizure event based upon at least one body parameter and coordinate data indicating position or motion of the patient. In one embodiment, the pulse generation device 14 can include a device for detecting the cardiac cycle, as one example of a body parameter or physiological condition of the human subject. There are many different ways to detect cardiac cycles, and several of these are shown in
As another alternative for monitoring the cardiac cycle of the subject 12, a pressure transducer 38 can be placed next to an artery, such as the carotid artery 40. It is to be appreciated that in the case of vagus nerve stimulation, the carotid artery 40 is relatively close to the vagus nerve 20 in the neck region. Thus, a surgeon could extend a branch 42 of the lead 16 toward the carotid artery during implantation of the nerve stimulation electrodes 18, and implant the pressure transducer 38. This pressure transducer detects changes in pressure adjacent to the artery, which are indicative of the cardiac cycle of the subject.
While the heart monitoring devices discussed above involve implanted structure, it is also to be appreciated that external devices can also be used for monitoring the subject's heart. For example, another method for detecting cardiac cycles can include the use of an external patch 44 which can be adhered to the skin of the chest of the subject 12 and can be similar to current Holter monitors. The patch can include a group of spaced electrodes (not shown), which detect the subject's ECG, in the same manner as implanted electrodes. The use of external adhesive electrodes for measuring the cardiac cycle is widely known in the medical arts. The patch 44 can include internal circuitry and a power source (not shown) and an antenna 46, so that the cardiac cycle information can be wirelessly transmitted to the pulse generation device 14. It is to be understood that, while the patch 44 is shown having an external antenna 46, this is for illustrative purposes only, and does not necessarily represent actual physical structure. It will be appreciated that the antenna can be an internal part of the patch device itself. This sort of patch can be a disposable device, which the subject can wear for a period of time and then replace with a new one whenever desired. The external patch is thus one example of an external communication device that can collect and/or receive seizure event data and threshold parameters associated with physical coordinates of the patient (e.g., GPS data).
It is to be appreciated that other heart monitoring devices, whether implanted or external, can be used in a seizure detection system as disclosed herein. For example, the discussion of the external patch 44 above applies equally to Holter monitors, which come in many varieties and sizes (e.g., simple strap versions commonly used during exercise or a larger “pager style” connected to multiple adhesive electrode patches). Whatever method is used for detecting the subject's cardiac cycle, data regarding the heart rate, heart rate variability, etc. of the subject are continuously transmitted back to the microprocessor 28 of the pulse generator 14. This allows the pulse generation device to be programmed to adjust nerve stimulation based upon the events detected from the cardiac cycle of the subject.
It is known that measurable parameters of cardiac activity correlate with epileptic seizure events. For example, an accelerated heart rate (tachycardia) often accompanies the onset of a seizure event. As used herein, the term “tachycardia” is used in a broader sense than that customarily used by cardiologists—it is used to generally refer to any increase in heart rate. When tachycardia is detected by the microprocessor 28, its programming can cause the pulse generation device to initiate nervous stimulation to treat the seizure. The microprocessor can include activation circuitry that is programmed and configured to activate the implantable device in response to at least one of the coordinate data and the body parameter or body signal data. In this way, the microprocessor 28 of the pulse generation device operates as an activation device for initiating nervous stimulation via the pulse generator. It is believed that nervous stimulation upon detection of a possible seizure can shorten the duration or lessen the severity of a seizure event. Moreover, it is believed that timely nervous stimulation upon first detection of seizure precursor symptoms can even prevent a seizure from fully developing. It is to be understood that to say that the seizure detector merely detects tachycardia can be a simplification. The algorithm for analyzing the cardiac cycle can do more than merely detect an elevated heart rate. Specifically, the algorithm may use matching techniques to identify tachycardia typical of seizures, use accelerometer or other data to confirm or deny seizure detections, or use linear or non-linear properties of heart rate variability (and it's derivatives) to detect or categorize seizure events.
One challenge to this methodology is that there are many possible causes for heart rate and cardiac cycle changes, such as physical exertion. The inventor has recognized that it is desirable to discriminate between the causes of cardiac cycle change when determining whether a seizure event has begun, and whether to trigger nerve stimulation for seizure control. The inventor has determined that information regarding an individual's activity or location can help distinguish cardiac cycle changes or other detectable physiological parameters that accompany a seizure from those that relate to other causes. Advantageously, the inventor has developed systems and methods disclosed herein for obtaining and using coordinate data related to the location of the human subject for more accurately identifying seizure events, and for determining a seizure threshold responsive to the coordinate data. In particular, in various embodiments, the apparatus and methods disclosed herein involve the use of GPS (Global Positioning System satellite data) or other coordinate measurement systems for seizure detection and logging specificity improvement.
GPS transceivers have become a common part of many electrical devices. For example, laptop computers, personal digital assistants (PDA's) and many or most smart phones now incorporate a GPS transceiver. The implanted vagus nerve stimulation system shown in
While the GPS transceiver 26 is shown incorporated into the implanted pulse generation device in
Having the GPS transceiver included within a device other than the pulse generation device 14 can be desirable for power conservation. It will be apparent that power consumption of a GPS transceiver that is in substantially constant communication with the GPS satellite system and a microprocessor that analyzes the positional information can use significant power, which is at a premium with implanted devices. Thus, having an external GPS device can reduce the power demands of the implanted device. Since the external device and the implanted device are presumably kept in relatively close proximity (both upon the person of the epileptic patient), wireless transmission between these devices can be at a much lower power than communication with the GPS system or some other wireless system, thus reducing the power demands upon the implanted device.
Additionally, microprocessing tasks and analysis can be transferred to an external device, rather than being performed by the microprocessor 28 of the pulse generation device, with the results of those microprocessing tasks transmitted to the implanted device. This can also conserve power for the implanted device. For example, the microprocessor associated with a smart phone 52 or wristwatch device 54 or some other external device can be programmed to receive cardiac cycle information (e.g, from an external heart monitoring device or transmitted from the pulse generator 14 or some other implanted device) as well as locational information (GPS, etc.), and perform the analysis discussed herein to distinguish seizure related tachycardia from other causes. The external device can then transmit operational commands or other information to the pulse generation device 14 that can affect its operation, when a seizure event is detected.
Having a GPS transceiver on or associated with the subject 12, along with an implanted or external seizure detector, such as a heart monitoring device, as shown in
A flowchart outlining the basic steps in this method is provided in
However, if a signal indicating a possible seizure (e.g., tachycardia or other signal) is received (at step 506), the system then determines whether a seizure is probably occurring (step 508). This analysis is based upon the modified seizure detection threshold that is part of a seizure detection algorithm, which was determined at step 502, as represented by dashed arrow 510. The difference between analytical steps 506 and 508 is the difference between possible and probable. Step 506 merely determines that a seizure is possible, based upon the received signal. At step 508, it is determined whether a seizure is probable or not, based upon the modified seizure detection threshold. As noted above, once the system has determined, from the coordinate data, how to adjust the seizure detection threshold, its ability to selectively identify a probable seizure is improved. If, in view of the modified seizure detection threshold, it is determined that the detected signal indicating a possible seizure is not likely to be indicative of a seizure, the system can again return to step 500 and continue to monitor and receive the coordinate data, and periodically adjust the seizure detection threshold (step 502). However, if a seizure is detected in view of the modified seizure detection threshold, one or more of various actions can be initiated, as indicated in boxes 512, 514 and 516. These are discussed in more detail below.
The configuration described above allows the system to be used in a variety of ways, some of which are illustrated in
Similarly, the microprocessor can incorporate automotive travel logic into the seizure detection algorithm to account for instances when the defined location of the person is mobile. Shown in
The seizure detection threshold can also vary depending upon the person's relationship to the vehicle—i.e. whether a driver or passenger. For example, tachycardia can be considered more likely for a driver 312, especially in crowded or difficult traffic conditions, than for a passenger 318, as shown in
In this way the coordinate data interface prompts the user to provide information that can identify their location, thus allowing any location to become a user-defined or designated location. In one embodiment, the coordinate data interface can display a predetermined list of location types, from which the user can select to identify the location. For example, the display may list “home”, “work”, “shopping” and “vehicle” as possible location choices. Multiple nested lists can be involved. When the user selects one, the system can then store the coordinate data of that location in conjunction with the identifier. In another embodiment, the coordinate data interface can be configured to receive an identifying name for the defined location via input of the user or a caretaker or medical personnel, for example. The named location can also have a location type associated with it, such as via a predetermined list of location types, in the manner discussed above.
The system can also prompt for risk factor inputs. These risk factor inputs can then be associated with physical coordinates of a defined location, and can be used to determine the seizure threshold responsive to the risk factor inputs and the coordinate data. The seizure detection algorithm's thresholds can be lowered to be more sensitive to possible seizures when the user is in a risky location. The risk of harm to the user increases in locations such as the gym, swimming pool, bath tub, driver's seat of a vehicle, kitchen, staircase, on a bicycle, and so forth. Each location can have a corresponding risk factor associated with it or the user can input the risk factor necessary for a certain location. The risk factor input can simply be the coordinate data and modify the risk factor dynamically as the user, for example, moves through the house from the bed, to the bath tub, to the kitchen, to the dining room, and then to the vehicle. The user can also input the risk factor by defining a location (e.g., a bicycle) as the user arrives at the location. The user can also input a risk factor without defining the location by, for example, setting a high risk factor when rock climbing and then input a low risk factor when the user eats a picnic lunch near the rock he climbed.
After the user has been prompted to enter relevant information, the system can then adjust the seizure detection threshold. In one embodiment, if a person is a passenger, the seizure detection algorithm can operate normally, but if the person is a driver, the algorithm can become more aggressive (e.g., lowering a threshold) to act upon every possible seizure, for example. Alternatively, the system can use the knowledge that the patient is the driver to separate out tachycardia induced by the stress of driving from tachycardia (or other cardiac cycle events) resulting from seizures.
While much of the above discussion has considered seizure detection based upon sensing tachycardia and cardiac cycles, it is to be understood that this is only one example of a body parameter or physiological condition that can be indicative of a possible seizure event. It is to be appreciated that seizure detection can be accomplished using any one or more of a wide variety of body parameters, in addition to cardiac cycles. For example, seizure detection data can be obtained from cardiovascular signals, respiratory signals, skin signals, pupillary signals, temperature signals, peristaltic signals, brain signals, cranial nerve signals, spinal cord signals, peripheral nerve signals, autonomic nerve or ganglia signals, biomedical presence or concentration signals (i.e. detection of a particular chemical species), body kinetic, position and force signals, and others. Additionally or alternatively, neurological signals, such as those generated by the brain or cranial nerves can be used for detecting a seizure. Exemplary body parameter sensor(s) can include electrocardiography (EKG) devices, accelerometers, inclinometers, pupillometers, face or body temperature monitors, skin resistance monitors, and/or sound and pressure sensors, among others. Those of skill in the art will be aware that sensor(s) to detect these and other body parameters are commercially available, and can be placed in, on, or near a particular organ, tissue, nerve, or blood vessel of the patient, or outside the patient's body, such as on the patient's skin or in the patient's environment.
Referring back to
Additionally, upon detection of a seizure the seizure detection system can begin recording data of the patient and other conditions, perhaps at a faster rate than normally. For example, if the system normally checks position and motion at a rate of once every 4 seconds when no seizure is detected, detection of a seizure could initiate electronic recording of the person's location, movement, heart rate, blood pressure, and other possible factors at a much higher refresh rate—e.g. every 1 second—during the seizure event. This information can be recorded or logged by the microprocessor (step 514) and/or transmitted to a remote location (step 516) if desired. A remote monitoring location or facility can also include its own wireless communication capability, as indicated by antenna 330, to allow direct communications with seizure detection systems, as opposed to or in addition to communications through the PSTN 326.
It is also to be appreciated that the seizure detection system can be used when there is no implanted nerve stimulation device. That is, for purposes of studying seizures, it may be desirable to provide a patient with heart monitoring devices, as discussed above, and an external device of some kind to detect and transmit data regarding seizures, even in the absence of any mechanism for treating them. This approach can be suitable for some patients and desirable from a research standpoint to gather seizure information.
The system can also be configured for other functions and for operation in other conditions, as shown in
The system can also incorporate neural network self-programming, so that the adaptive thresholds “learn” to match a particular patient's pattern of how speed and altitude changes result in heart rate changes. Over time, the adaptive threshold can be “trained” to follow an expected pattern of exertion versus resulting heart rate (or other autonomic) change. A seizure detection declaration is made to be more likely when the pattern of cardiac cycle deviates from the cardiac cycle that would have normally been expected given contemporary velocity data.
In addition to adjusting an adaptive heart rate threshold in conjunction with data regarding velocity or motion of the individual, the system can also use GPS positional or coordinate data to modify the seizure detection threshold based on specific coordinate locations. That is, the system can use a logical neural network self-programming and learning for recognizing specific positional patterns. For example, using data from a GPS satellite system 406, the system can logically determine that the patient is in a position of a bed 408 (e.g. on an upper floor 410 of a known residential building 404, in a substantially constant position for several continuous hours each day). If a ‘bed’ locational determination is made, adaptive thresholds can be adjusted to attempt to discriminate from patterns of normal sleep behaviors. Where the system determines this type of location, sudden tachycardia can be indicative either of a seizure event, or of waking and rising. To distinguish between sudden heart rate change due to a seizure and sudden heart rate change upon getting out of bed, the system can be programmed to recognize that a heart rate jump upon arising from bed is likely to occur after a change in body position. Consequently, GPS or other signals that detect body or positional changes can screen this out.
Similarly, logical determination that the patient is in a position of a car's normal patterned parking space (i.e., within a garage 412 of a residence 404) can trigger corresponding logical conclusions. If a ‘car’ locational determination is made, adaptive thresholds can be adjusted to ‘automotive travel’ mode immediately, rather than having to wait for a pattern of velocity that indicates automotive travel.
Relevant data can also be obtained from devices in addition to a GPS transceiver. For example, as shown in
As noted above, receiving GPS signals generally requires a line of sight to GPS satellites. However, there are many locations, such as inside a building, etc., where it may be difficult or impossible to obtain a GPS signal. Such a situation is suggested in
Additionally, other position-finding technologies can also be used to determine location when a GPS signal is limited, such as at certain indoor locations. Other position-finding technologies that can be used can include local positioning systems, RFID systems, toll tag technologies, cell phone positional methodologies, internal radio positional networks, proximity sensors, motion sensors, and acoustic broadcasts and sensors (especially those tuned to inaudible frequencies) which can determine the location and/or motion of a patient in many locations. These types of systems can provide a local coordinate system that can provide local coordinate data regarding the position or motion of the patient. One of these types of systems is suggested in
These detection devices 414 can be sensors which actually sense position and/or motion (e.g. motion detectors), or they can be broadcast devices that broadcast a signal (e.g. a radio signal), and then sense reflected information. For example, the detection devices 414 can provide signals (e.g. proximity signals) to an IMD or external device upon the person of the patient, and the IMD or external device can then interpret the proximity data to independently determine the position and motion of the patient to detect the patient 400 climbing a flight of stairs 402, for example, even if the GPS system is not able to detect it. Similarly, the detection devices can detect when the person is sitting relatively still, as at 416, or in or near the bed 408. The detection devices 414 for this type of application can be cell phone positional sensors, an internal radio positional network, proximity sensors, motion sensors, or others. Thus, for example, viewing
In an interior or other location where a GPS signal may not be available, the user can ‘set up’ the home or commonly visited place with detection devices of two or more types. One type of detection device can be used to indicate that the area is associated with a ‘high risk’. Another type of detection device can be associated with a ‘low risk’ location. In instances when there is only one type of detection device present, the default programming can consider decision making without the condition of ‘high risk’ or ‘low risk’ biasing the decision.
In the case of a tachycardia-based detection algorithm, one example of a high risk location can be the person's the bed 208, since tachycardia when in one's bed should be rare except in the event of an actual seizure. As another example, a bathtub (not shown) can be considered a high risk location because, even though non-seizure tachycardia could happen in the bathtub, the consequences of an unattended seizure in the bathtub carry high risk. In high risk locations the propensity to declare an event and respond can be biased toward more vigilance. On the other hand, an example of a low risk location could be a stairway 402. It is highly probable that tachycardia will be associated with exertion in a stairway. Consequently, the threshold for seizure responsive action in a stairway can be relaxed, since a tachycardia event experienced at the stairway is more likely to be due to exertion, rather than a seizure event.
The locational data that is collected when setting up the commonly visited locations can also be presented for use in patient care. For example, medical professionals, caregivers, and/or patients can analyze the patient's sleeping habits, daily rituals, frequency of exposure to ‘high risk’ locations, the amount of time spent in particular locations of interest, and general activity levels. These types of factors can be referred to as lifestyle factors, and can be evaluated and considered in the seizure detection system disclosed herein. For example, this data can help determine the patient's quality of life or, among other things, behavioral patterns that may lead to changes in the prescribed therapy. The conglomerated and trended positional and body sensor data may be used to collaterally quantify and communicate lifestyle factors such as in the form of standard indices like Physical Activity Level (PAL)/Physical Activity Index (PAI), Total Energy Expenditure (TEE), and other existing standards used to quantify state of health. Such indices and their trends may themselves be used to adjust a seizure detection declaration threshold, reveal trends that may be predictive of seizure propensity, or simply for presenting a measure of health improvement or decline to the healthcare provider.
An additional feature of the seizure detection system shown in
Alternatively, in an embodiment, similar to
It is to be appreciated that the system and method disclosed herein can also apply to cardiac pacemakers. That is, a pacemaker is an implantable device that can be provided with a coordinate data interface in the manner disclosed herein, and include programming to determine or adjust operational parameters based upon coordinate and/or motion data and a detected physiological condition, such as cardiac cycles.
The system and method disclosed herein can thus improve the accuracy of automated seizure detection devices and algorithms. This system has the greatest potential to improve specificity of automated seizure declarations. It can reduce battery consumption by an implanted nerve stimulation device by avoiding false alarms and incorrectly identified needs for therapy delivery. It can also reduce anxiety and disruption by avoiding false alarms for alerting-type systems. Additionally, this system and method can improve the tracking of disease progression by making seizure counts more accurate.
Although various embodiments have been shown and described, the invention is not so limited and will be understood to include all such modifications and variations as would be apparent to one skilled in the art. For example, equivalent elements may be substituted for those specifically shown and described, certain features may be used independently of other features, and the number and configuration of various vehicle components described above may be altered, all without departing from the spirit or scope of the invention as defined in the appended claims.
Such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed exemplary embodiments. It is to be understood that the phraseology of terminology employed herein is for the purpose of description and not of limitation. Accordingly, the foregoing description of the exemplary embodiments of the invention, as set forth above, are intended to be illustrative, not limiting. Various changes, modifications, and/or adaptations may be made without departing from the spirit and scope of this invention.
Number | Name | Date | Kind |
---|---|---|---|
4172459 | Hepp | Oct 1979 | A |
4197856 | Northrop | Apr 1980 | A |
4291699 | Geddes et al. | Sep 1981 | A |
4320766 | Alihanka et al. | Mar 1982 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4702254 | Zabara | Oct 1987 | A |
4867164 | Zabara | Sep 1989 | A |
4920979 | Bullara | May 1990 | A |
4949721 | Toriu et al. | Aug 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
5025807 | Zabara | Jun 1991 | A |
5062169 | Kennedy et al. | Nov 1991 | A |
5113869 | Nappholz et al. | May 1992 | A |
5137020 | Wayne et al. | Aug 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5194847 | Taylor et al. | Mar 1993 | A |
5203326 | Collins | Apr 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5213568 | Lattin et al. | May 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5237991 | Baker, Jr. et al. | Aug 1993 | A |
5243980 | Mehra | Sep 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269302 | Swartz et al. | Dec 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5311876 | Olsen et al. | May 1994 | A |
5313953 | Yomtov et al. | May 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5425373 | Causey, III | Jun 1995 | A |
5513649 | Gevins et al. | May 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5523742 | Simkins et al. | Jun 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5610590 | Johnson et al. | Mar 1997 | A |
5611350 | John | Mar 1997 | A |
5645077 | Foxlin | Jul 1997 | A |
5645570 | Corbucci | Jul 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5683422 | Rise et al. | Nov 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690688 | Noren et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5720771 | Snell | Feb 1998 | A |
5743860 | Hively et al. | Apr 1998 | A |
5748113 | Torch | May 1998 | A |
5792186 | Rise | Aug 1998 | A |
5800474 | Benabid et al. | Sep 1998 | A |
5807284 | Foxlin | Sep 1998 | A |
5808552 | Wiley et al. | Sep 1998 | A |
5833709 | Rise et al. | Nov 1998 | A |
5853005 | Scanlon et al. | Dec 1998 | A |
5879309 | Johnson et al. | Mar 1999 | A |
5905436 | Dwight et al. | May 1999 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916181 | Socci et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
5942979 | Luppino | Aug 1999 | A |
5978702 | Ward et al. | Nov 1999 | A |
5978972 | Stewart et al. | Nov 1999 | A |
5987352 | Klein et al. | Nov 1999 | A |
5995868 | Osorio et al. | Nov 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6018682 | Rise | Jan 2000 | A |
6048324 | Socci et al. | Apr 2000 | A |
6061593 | Fischell et al. | May 2000 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6083249 | Familoni | Jul 2000 | A |
6091992 | Bourgeois et al. | Jul 2000 | A |
6095991 | Krausman et al. | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6115630 | Stadler et al. | Sep 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6162191 | Foxlin | Dec 2000 | A |
6163281 | Torch | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6171239 | Humphrey | Jan 2001 | B1 |
6175764 | Loeb et al. | Jan 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6221908 | Kilgard et al. | Apr 2001 | B1 |
6246344 | Torch | Jun 2001 | B1 |
6248080 | Miesel et al. | Jun 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6272379 | Fischell et al. | Aug 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6315740 | Singh | Nov 2001 | B1 |
6324421 | Stadler et al. | Nov 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6361507 | Foxlin | Mar 2002 | B1 |
6361508 | Johnson et al. | Mar 2002 | B1 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6366814 | Boveja | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6397100 | Stadler et al. | May 2002 | B2 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6429217 | Puskas | Aug 2002 | B1 |
6441731 | Hess | Aug 2002 | B1 |
6449512 | Boveja | Sep 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6463328 | John | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477418 | Plicchi et al. | Nov 2002 | B2 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6484132 | Hively et al. | Nov 2002 | B1 |
6501983 | Natarajan et al. | Dec 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6539263 | Schiff et al. | Mar 2003 | B1 |
6542081 | Torch | Apr 2003 | B2 |
6542774 | Hill et al. | Apr 2003 | B2 |
6549804 | Osorio et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6560486 | Osorio et al. | May 2003 | B1 |
6564102 | Boveja | May 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6594524 | Esteller et al. | Jul 2003 | B2 |
6599250 | Webb et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6611783 | Kelly, Jr. et al. | Aug 2003 | B2 |
6615081 | Boveja | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628985 | Sweeney et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6629990 | Putz et al. | Oct 2003 | B2 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6656125 | Misczynski et al. | Dec 2003 | B2 |
6656960 | Puskas | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671555 | Gielen et al. | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6730047 | Socci et al. | May 2004 | B2 |
6735474 | Loeb et al. | May 2004 | B1 |
6738671 | Christophersom et al. | May 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6763256 | Kimball et al. | Jul 2004 | B2 |
6768969 | Nikitin et al. | Jul 2004 | B1 |
6786877 | Foxlin | Sep 2004 | B2 |
6788975 | Whitehurst et al. | Sep 2004 | B1 |
6793670 | Osorio et al. | Sep 2004 | B2 |
6819953 | Yonce et al. | Nov 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6836685 | Fitz | Dec 2004 | B1 |
6850601 | Jones et al. | Feb 2005 | B2 |
6879850 | Kimball | Apr 2005 | B2 |
6882881 | Lesser et al. | Apr 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6904390 | Nikitin et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6923784 | Stein | Aug 2005 | B2 |
6931274 | Williams et al. | Aug 2005 | B2 |
6934580 | Osorio et al. | Aug 2005 | B1 |
6934585 | Schloss | Aug 2005 | B1 |
6944501 | Pless | Sep 2005 | B1 |
6957107 | Rogers | Oct 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6984993 | Ariav | Jan 2006 | B2 |
6985771 | Fischell et al. | Jan 2006 | B2 |
6990377 | Gliner et al. | Jan 2006 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7006872 | Gielen et al. | Feb 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7024247 | Gliner et al. | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7054792 | Frei et al. | May 2006 | B2 |
7058453 | Nelson et al. | Jun 2006 | B2 |
7068842 | Liang et al. | Jun 2006 | B2 |
7076288 | Skinner | Jul 2006 | B2 |
7077810 | Lange et al. | Jul 2006 | B2 |
7079977 | Osorio et al. | Jul 2006 | B2 |
7104947 | Riehl et al. | Sep 2006 | B2 |
7110820 | Tcheng et al. | Sep 2006 | B2 |
7112319 | Broderick et al. | Sep 2006 | B2 |
7127370 | Kelly et al. | Oct 2006 | B2 |
7134996 | Bardy | Nov 2006 | B2 |
7139677 | Hively et al. | Nov 2006 | B2 |
7146211 | Frei et al. | Dec 2006 | B2 |
7146217 | Firlik et al. | Dec 2006 | B2 |
7146218 | Esteller et al. | Dec 2006 | B2 |
7149572 | Frei et al. | Dec 2006 | B2 |
7164941 | Misczynski et al. | Jan 2007 | B2 |
7167743 | Heruth et al. | Jan 2007 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174206 | Frei et al. | Feb 2007 | B2 |
7177678 | Osorio et al. | Feb 2007 | B1 |
7188053 | Nikitin et al. | Mar 2007 | B2 |
RE39539 | Torch | Apr 2007 | E |
7204833 | Osorio et al. | Apr 2007 | B1 |
7209786 | Brockway | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7221981 | Gliner | May 2007 | B2 |
7228167 | Kara | Jun 2007 | B2 |
7231254 | DiLorenzo | Jun 2007 | B2 |
7236830 | Gliner | Jun 2007 | B2 |
7236831 | Firlik et al. | Jun 2007 | B2 |
7242983 | Frei et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7254439 | Misczynski et al. | Aug 2007 | B2 |
7263467 | Sackellares et al. | Aug 2007 | B2 |
7274298 | Frank | Sep 2007 | B2 |
7277758 | DiLorenzo | Oct 2007 | B2 |
7280867 | Frei et al. | Oct 2007 | B2 |
7282030 | Frei et al. | Oct 2007 | B2 |
7289844 | Misczynski et al. | Oct 2007 | B2 |
7292890 | Whitehurst et al. | Nov 2007 | B2 |
7295881 | Cohen et al. | Nov 2007 | B2 |
7299096 | Balzer et al. | Nov 2007 | B2 |
7302298 | Lowry et al. | Nov 2007 | B2 |
7304580 | Sullivan et al. | Dec 2007 | B2 |
7305268 | Gliner et al. | Dec 2007 | B2 |
7313440 | Miesel | Dec 2007 | B2 |
7314451 | Halperin et al. | Jan 2008 | B2 |
7321837 | Osorio et al. | Jan 2008 | B2 |
7324850 | Persen et al. | Jan 2008 | B2 |
7324851 | DiLorenzo | Jan 2008 | B1 |
7330760 | Heruth et al. | Feb 2008 | B2 |
7346391 | Osorio et al. | Mar 2008 | B1 |
7353063 | Simms, Jr. | Apr 2008 | B2 |
7353064 | Gliner et al. | Apr 2008 | B2 |
7373199 | Sackellares et al. | May 2008 | B2 |
7385443 | Denison | Jun 2008 | B1 |
7389144 | Osorio et al. | Jun 2008 | B1 |
7389147 | Wahlstrand et al. | Jun 2008 | B2 |
7395113 | Heruth et al. | Jul 2008 | B2 |
7401008 | Frei et al. | Jul 2008 | B2 |
7403820 | DiLorenzo | Jul 2008 | B2 |
7420472 | Tran | Sep 2008 | B2 |
7433732 | Carney et al. | Oct 2008 | B1 |
7447545 | Heruth et al. | Nov 2008 | B2 |
7454245 | Armstrong et al. | Nov 2008 | B2 |
7488293 | Marcovecchio et al. | Feb 2009 | B2 |
7488294 | Torch | Feb 2009 | B2 |
7491181 | Heruth et al. | Feb 2009 | B2 |
7494464 | Rzesnitzek et al. | Feb 2009 | B2 |
7502643 | Farringdon et al. | Mar 2009 | B2 |
7515054 | Torch | Apr 2009 | B2 |
7539532 | Tran | May 2009 | B2 |
7539533 | Tran | May 2009 | B2 |
7539543 | Schiff et al. | May 2009 | B2 |
7558622 | Tran | Jul 2009 | B2 |
7565132 | Ben | Jul 2009 | B2 |
7590453 | Heruth et al. | Sep 2009 | B2 |
7612680 | Eubank et al. | Nov 2009 | B2 |
7620456 | Gliner et al. | Nov 2009 | B2 |
7629890 | Sullivan et al. | Dec 2009 | B2 |
7643655 | Liang et al. | Jan 2010 | B2 |
7647121 | Wahlstrand et al. | Jan 2010 | B2 |
7658112 | Nakamura | Feb 2010 | B2 |
7666151 | Sullivan et al. | Feb 2010 | B2 |
7714757 | Denison et al. | May 2010 | B2 |
7717848 | Heruth et al. | May 2010 | B2 |
RE41376 | Torch | Jun 2010 | E |
7733224 | Tran | Jun 2010 | B2 |
7747318 | John et al. | Jun 2010 | B2 |
7769464 | Gerber et al. | Aug 2010 | B2 |
7775993 | Heruth et al. | Aug 2010 | B2 |
7792583 | Miesel et al. | Sep 2010 | B2 |
7801603 | Westlund et al. | Sep 2010 | B2 |
7801618 | Pless | Sep 2010 | B2 |
7801743 | Graves et al. | Sep 2010 | B2 |
7813802 | Tcheng et al. | Oct 2010 | B2 |
7822481 | Gerber et al. | Oct 2010 | B2 |
7827011 | Devaul et al. | Nov 2010 | B2 |
7831305 | Gliner | Nov 2010 | B2 |
7847628 | Denison | Dec 2010 | B2 |
7866212 | Ariav et al. | Jan 2011 | B2 |
7899545 | John | Mar 2011 | B2 |
7935076 | Estes et al. | May 2011 | B2 |
RE42471 | Torch | Jun 2011 | E |
7957809 | Bourget et al. | Jun 2011 | B2 |
7965833 | Meir et al. | Jun 2011 | B2 |
7974671 | Fujiwara et al. | Jul 2011 | B2 |
7996076 | Burns et al. | Aug 2011 | B2 |
7999857 | Bunn et al. | Aug 2011 | B2 |
8000789 | Denison et al. | Aug 2011 | B2 |
8000794 | Lozano | Aug 2011 | B2 |
8021299 | Miesel et al. | Sep 2011 | B2 |
8027730 | John et al. | Sep 2011 | B2 |
8027737 | Kokones et al. | Sep 2011 | B2 |
8075499 | Nathan et al. | Dec 2011 | B2 |
8109891 | Kramer et al. | Feb 2012 | B2 |
20010032059 | Kelly et al. | Oct 2001 | A1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020151939 | Rezai | Oct 2002 | A1 |
20020188214 | Misczynski et al. | Dec 2002 | A1 |
20030040680 | Hassert et al. | Feb 2003 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030083716 | Nicolelis et al. | May 2003 | A1 |
20030083726 | Zeijlemaker et al. | May 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield et al. | Jul 2003 | A1 |
20030144829 | Geatz et al. | Jul 2003 | A1 |
20030181954 | Rezai | Sep 2003 | A1 |
20030181958 | Dobak | Sep 2003 | A1 |
20030195588 | Upton et al. | Oct 2003 | A1 |
20030208212 | Cigaina | Nov 2003 | A1 |
20030210147 | Humbard | Nov 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030236474 | Singh | Dec 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040006278 | Webb et al. | Jan 2004 | A1 |
20040030365 | Rubin et al. | Feb 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040111045 | Sullivan et al. | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040122485 | Stahmann et al. | Jun 2004 | A1 |
20040133119 | Osorio et al. | Jul 2004 | A1 |
20040138516 | Osorio et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138647 | Osorio et al. | Jul 2004 | A1 |
20040138711 | Osorio et al. | Jul 2004 | A1 |
20040153129 | Pless et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040158165 | Yonce et al. | Aug 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172091 | Rezai | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040176831 | Gliner et al. | Sep 2004 | A1 |
20040199212 | Fischell et al. | Oct 2004 | A1 |
20040225335 | Whitehurst et al. | Nov 2004 | A1 |
20040249302 | Donoghue et al. | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050020887 | Goldberg | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021106 | Firlik et al. | Jan 2005 | A1 |
20050021107 | Firlik et al. | Jan 2005 | A1 |
20050021118 | Genau et al. | Jan 2005 | A1 |
20050022606 | Partin et al. | Feb 2005 | A1 |
20050027284 | Lozano et al. | Feb 2005 | A1 |
20050033378 | Sheffield et al. | Feb 2005 | A1 |
20050033379 | Lozano et al. | Feb 2005 | A1 |
20050038484 | Knudson et al. | Feb 2005 | A1 |
20050049515 | Misczynski et al. | Mar 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050060001 | Singhal et al. | Mar 2005 | A1 |
20050065562 | Rezai | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065574 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070971 | Fowler et al. | Mar 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050101873 | Misczynski et al. | May 2005 | A1 |
20050107716 | Eaton et al. | May 2005 | A1 |
20050119703 | DiLorenzo | Jun 2005 | A1 |
20050124901 | Misczynski et al. | Jun 2005 | A1 |
20050131467 | Boveja et al. | Jun 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050143786 | Boveja et al. | Jun 2005 | A1 |
20050148893 | Misczynski et al. | Jul 2005 | A1 |
20050148894 | Misczynski et al. | Jul 2005 | A1 |
20050148895 | Misczynski et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197590 | Osorio et al. | Sep 2005 | A1 |
20050203366 | Donoghue et al. | Sep 2005 | A1 |
20050245971 | Brockway et al. | Nov 2005 | A1 |
20050261542 | Riehl | Nov 2005 | A1 |
20050277998 | Tracey et al. | Dec 2005 | A1 |
20050283200 | Rezai et al. | Dec 2005 | A1 |
20050283201 | Machado et al. | Dec 2005 | A1 |
20050288600 | Zhang et al. | Dec 2005 | A1 |
20050288760 | Machado et al. | Dec 2005 | A1 |
20060009815 | Boveja | Jan 2006 | A1 |
20060018833 | Murphy et al. | Jan 2006 | A1 |
20060074450 | Boveja | Apr 2006 | A1 |
20060079936 | Boveja | Apr 2006 | A1 |
20060094971 | Drew | May 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060135877 | Giftakis et al. | Jun 2006 | A1 |
20060135881 | Giftakis et al. | Jun 2006 | A1 |
20060149139 | Bonmassar et al. | Jul 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173522 | Osorio | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195163 | KenKnight et al. | Aug 2006 | A1 |
20060200206 | Firlik et al. | Sep 2006 | A1 |
20060212091 | Lozano et al. | Sep 2006 | A1 |
20060212097 | Varadan et al. | Sep 2006 | A1 |
20060224067 | Giftakis et al. | Oct 2006 | A1 |
20060224191 | DiLorenzo | Oct 2006 | A1 |
20060241697 | Libbus et al. | Oct 2006 | A1 |
20060241725 | Libbus et al. | Oct 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20070027486 | Armstrong et al. | Feb 2007 | A1 |
20070027497 | Parnis et al. | Feb 2007 | A1 |
20070027498 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070043392 | Gliner et al. | Feb 2007 | A1 |
20070055320 | Weinand et al. | Mar 2007 | A1 |
20070073150 | Gopalsami et al. | Mar 2007 | A1 |
20070073355 | Dilorenzo | Mar 2007 | A1 |
20070088403 | Wyler et al. | Apr 2007 | A1 |
20070100278 | Frei et al. | May 2007 | A1 |
20070100392 | Maschino et al. | May 2007 | A1 |
20070142862 | Dilorenzo | Jun 2007 | A1 |
20070142873 | Esteller et al. | Jun 2007 | A1 |
20070150024 | Leyde et al. | Jun 2007 | A1 |
20070150025 | Dilorenzo et al. | Jun 2007 | A1 |
20070161919 | DiLorenzo | Jul 2007 | A1 |
20070162086 | DiLorenzo | Jul 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070173901 | Reeve | Jul 2007 | A1 |
20070173902 | Maschino et al. | Jul 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070179557 | Maschino et al. | Aug 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070213785 | Osorio et al. | Sep 2007 | A1 |
20070233192 | Craig | Oct 2007 | A1 |
20070239210 | Libbus et al. | Oct 2007 | A1 |
20070242661 | Tran et al. | Oct 2007 | A1 |
20070244407 | Osorio | Oct 2007 | A1 |
20070249953 | Osario et al. | Oct 2007 | A1 |
20070249954 | Virag et al. | Oct 2007 | A1 |
20070255147 | Drew et al. | Nov 2007 | A1 |
20070255155 | Drew et al. | Nov 2007 | A1 |
20070260147 | Giftakis et al. | Nov 2007 | A1 |
20070260289 | Giftakis et al. | Nov 2007 | A1 |
20070265536 | Giftakis et al. | Nov 2007 | A1 |
20070272260 | Nikitin et al. | Nov 2007 | A1 |
20070282177 | Pilz | Dec 2007 | A1 |
20080004904 | Tran et al. | Jan 2008 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080033508 | Frei et al. | Feb 2008 | A1 |
20080046035 | Fowler et al. | Feb 2008 | A1 |
20080064934 | Frei et al. | Mar 2008 | A1 |
20080071323 | Lowry et al. | Mar 2008 | A1 |
20080077028 | Schaldach et al. | Mar 2008 | A1 |
20080081958 | Denison et al. | Apr 2008 | A1 |
20080103548 | Fowler et al. | May 2008 | A1 |
20080114417 | Leyde | May 2008 | A1 |
20080119900 | DiLorenzo | May 2008 | A1 |
20080125820 | Stahmann et al. | May 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
20080146890 | LeBoeuf et al. | Jun 2008 | A1 |
20080146959 | Sheffield et al. | Jun 2008 | A1 |
20080161712 | Leyde | Jul 2008 | A1 |
20080161713 | Leyde et al. | Jul 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161880 | Firlik et al. | Jul 2008 | A1 |
20080161881 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080183096 | Snyder et al. | Jul 2008 | A1 |
20080183097 | Leyde et al. | Jul 2008 | A1 |
20080208013 | Zhang et al. | Aug 2008 | A1 |
20080208284 | Rezai et al. | Aug 2008 | A1 |
20080258907 | Kalpaxis et al. | Oct 2008 | A1 |
20080269579 | Schiebler et al. | Oct 2008 | A1 |
20080275327 | Faarbaek et al. | Nov 2008 | A1 |
20080275328 | Jones et al. | Nov 2008 | A1 |
20080275349 | Halperin et al. | Nov 2008 | A1 |
20080281376 | Gerber et al. | Nov 2008 | A1 |
20080281381 | Gerber et al. | Nov 2008 | A1 |
20080281550 | Hogle et al. | Nov 2008 | A1 |
20080319281 | Aarts et al. | Dec 2008 | A1 |
20090030345 | Bonnet et al. | Jan 2009 | A1 |
20090040052 | Cameron et al. | Feb 2009 | A1 |
20090054737 | Magar et al. | Feb 2009 | A1 |
20090054742 | Kaminska et al. | Feb 2009 | A1 |
20090060287 | Hyde et al. | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090099624 | Kokones et al. | Apr 2009 | A1 |
20090099627 | Molnar et al. | Apr 2009 | A1 |
20090105785 | Wei et al. | Apr 2009 | A1 |
20090137921 | Kramer et al. | May 2009 | A1 |
20090227882 | Foo | Sep 2009 | A1 |
20090227888 | Salmi | Sep 2009 | A1 |
20090322540 | Richardson et al. | Dec 2009 | A1 |
20100010382 | Panken | Jan 2010 | A1 |
20100010392 | Skelton et al. | Jan 2010 | A1 |
20100010583 | Panken et al. | Jan 2010 | A1 |
20100023348 | Hardee et al. | Jan 2010 | A1 |
20100056878 | Partin et al. | Mar 2010 | A1 |
20100106217 | Colborn | Apr 2010 | A1 |
20100109875 | Ayon et al. | May 2010 | A1 |
20100121214 | Giftakis et al. | May 2010 | A1 |
20100217533 | Nadkarni et al. | Aug 2010 | A1 |
20100223020 | Goetz | Sep 2010 | A1 |
20100228103 | Schecter | Sep 2010 | A1 |
20100228314 | Goetz | Sep 2010 | A1 |
20100268056 | Picard et al. | Oct 2010 | A1 |
20100280336 | Giftakis et al. | Nov 2010 | A1 |
20100280578 | Skelton et al. | Nov 2010 | A1 |
20100280579 | Denison et al. | Nov 2010 | A1 |
20100286567 | Wolfe et al. | Nov 2010 | A1 |
20100298661 | McCombie et al. | Nov 2010 | A1 |
20100298742 | Perlman et al. | Nov 2010 | A1 |
20100305665 | Miesel et al. | Dec 2010 | A1 |
20100312188 | Robertson et al. | Dec 2010 | A1 |
20110029044 | Hyde et al. | Feb 2011 | A1 |
20110040204 | Ivorra et al. | Feb 2011 | A1 |
20110040546 | Gerber et al. | Feb 2011 | A1 |
20110060252 | Simonsen et al. | Mar 2011 | A1 |
20110066062 | Banet et al. | Mar 2011 | A1 |
20110066081 | Goto et al. | Mar 2011 | A1 |
20110137372 | Makous et al. | Jun 2011 | A1 |
20110172545 | Grudic et al. | Jul 2011 | A1 |
20110230730 | Quigg et al. | Sep 2011 | A1 |
20110245629 | Giftakis et al. | Oct 2011 | A1 |
20110251469 | Varadan | Oct 2011 | A1 |
20110270117 | Warwick et al. | Nov 2011 | A1 |
20110270134 | Skelton et al. | Nov 2011 | A1 |
20110295127 | Sandler et al. | Dec 2011 | A1 |
20110306846 | Osorio | Dec 2011 | A1 |
20110313484 | Hincapie et al. | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
1145736 | Oct 2001 | EP |
1486232 | Dec 2004 | EP |
2026870 | Feb 1980 | GB |
2079610 | Jan 1982 | GB |
0064336 | Nov 2000 | WO |
2004036377 | Apr 2004 | WO |
2005007120 | Jan 2005 | WO |
2005053788 | Jun 2005 | WO |
2005067599 | Jul 2005 | WO |
2006050144 | May 2006 | WO |
2006122148 | Nov 2006 | WO |
2007066343 | Jun 2007 | WO |
2007072425 | Jun 2007 | WO |
2007124126 | Nov 2007 | WO |
2007124190 | Nov 2007 | WO |
2007124192 | Nov 2007 | WO |
2007142523 | Dec 2007 | WO |
2008045597 | Apr 2008 | WO |
Entry |
---|
Bachman, D.,S. et al.; “Effects Of Vagal Volleys And Serotonin On Units Of Cingulate Cortex in Monkeys;” Brain Research, vol. 130 (1977), pp. 253-269. |
Baevsky, R.M. “Analysis of Heart Rate Variability in Space Medicine;” Human Physiology, vol. 28, No. 2, (2002); pp. 202-213. |
Baevsky, R.M., et al.; “Autonomic Cardiovascular and Respiratory Control During Prolonged Spaceflights Aboard the International Space Station;”J. Applied Physiological, vol. 103, (2007) pp. 156-161. |
Boon, P., et al.; “Vagus Nerve Stimulation for Epilepsy, Clinical Efficacy of Programmed and Magnet Stimulation;” (2001); pp. 93-98. |
Boon, Paul, et al.; “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;”Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407. |
Borovikova, L.V., et al.; “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin;” Letters to Nature; vol. 405; (May 2000); pp. 458-462. |
Brack, Kieran E., et al.; “Interaction Between Direct Sympathetic and Vagus Nerve Stimulation on Heart Rate in the Isolated Rabbit Heart;”Experimental Physiology vol. 89, No. 1; pp. 128-139. |
Chakravarthy, N., et al.; “Controlling Synchronization in a Neuron-Level Population Model;” International Journal of Neural Systems, vol. 17, No. 2 (2007) pp. 123-138. |
Clark, K.B., et al.; “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat;” Neurobiology of Learning and Memory, vol. 70, 364-373 (1998). |
Elmpt, W.J.C., et al.; “A Model of Heart Rate Changes to Detect Seizures in Severe Epilepsy” Seizure vol. 15, (2006) pp. 366-375. |
Frei, M.G., et al.; “Left Vagus Nerve Stimulation with the Neurocybernetic Prosthesis Has Complex Effects on Heart Rate and on Its Variability in Humans:” Epilepsia, vol. 42, No. 8 (2001); pp. 1007-1016. |
George, M.S., et al.; “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;”Society of Biological Psychiatry vol. 47 (2000) pp. 287-295. |
“Heart Rate Variability—Standards of Measurement, Physiological Interpretation, and Clinical Use” Circulation—Electrophysiology vol. 93, No. 5; http://circ.ahajournals.org/cgi/content-nw/full/93/5/1043/F3. |
Henry, Thomas R.; “Therapeutic Mechanisms of Vague Name Stimulation;”. Neurology, vol. 59 (Supp 4) (Sep. 2002), pp. S3-S14. |
Hallowitz et al., “Effects Of Vagal Volleys On Units Of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;”Brain Research, vol. 130 (1977), pp. 271-286. |
Iasemidis; L.D., et al.; “Dynamical Resetting of the Human Brain at Epilepctic Seizures: Application of Nonlinear Dynamics and Global Optimization Techniques;” IEEE Transactions on Biomedical Engineering, vol. 51, No. 3 (Mar. 2004); pp. 493-506. |
Iasemidis; L.D., et al.; “Spatiotemporal Transition to Epileptic Seizures: A Nonlinear Dynamical Analysis of Scalp and Intracranial EEG Recordings;”Spatiotemporal Models in Biological and Artificial Systems; F.L. Silva et al. (Eds.) IOS Press, 1997; pp. 81-88. |
Iasemidis, L.D.; “Epileptic Seizure Prediction and Control” IEEE Transactions on Biomedical Engineering, vol. 50, No. 5 (May 2003); pp. 549-558. |
Kautzner, J., et al.; “Utility of Short-Term Heart Rate Variability for Prediction of Sudden Cardiac Death After Acute Myocardial Infarction”Acta Univ. Palacki. Olomuc., Fac. Med., vol. 141 (1998) pp. 69-73. |
Koenig, S.A., et al.; “Vagus Nerve Stimulation Improves Severely Impaired Heart Rate Variability in a Patient with Lennox-Gastaut-Syndrome” Seizure (2007) Article in Press—Yseiz-1305; pp. 1-4. |
Koo, B., “EEG Changes With Vagus Nerve Stimulation” Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441. |
Krittayaphong, M.D., et al.; “Heart Rate Variability in Patients with Coronary Artery Disease: Differences in Patients with Higher and Lower Depression Scores” Psychosomatic Medicine vol. 59 (1997) pp. 231-235. |
Leutmezer, F., et al.; “Electrocardiographic Changes at the Onset of Epileptic Seizures;” Epilepsia, vol. 44, No. 3; (2003); pp. 348-354. |
Lewis, M.E., et al.; “Vagus Nerve Stimulation Decreases Left Ventricular Contractility in Vivo in the Human and Pig Heart” The Journal of Physiology vol. 534, No. 2, (2001) pp. 547-552. |
Li, M., et al.; “Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats:” Circulation (Jan. 2004) pp. 120-124. |
Licht, C.M.M.; Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (NESDA); Arch. Gen Psychiatry, vol. 65, No. 12 (Dec. 2008); pp. 1358-1367. |
Lockard et al., “Feasibility And Safety Of Vagal Stimulation In Monkey Model;” Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26. |
McClintock, P., “Can Noise Actually Boost Brain Power” Physics World Jul. 2002; pp. 20-21. |
Mori, T., et al.; “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves” Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4. |
Mormann, F., “Seizure prediction: the long and winding road,” Brain 130 (2007), 314-333. |
Nouri, M.D.; “Epilepsy and the Autonomic Nervous System” emedicine (updated May 5, 2006); pp. 1-14; http://www.emedicine.com/neuro/topic658.htm. |
O'Regan, M.E., et al.; “Abnormalities in Cardiac and Respiratory Function Observed During Seizures in Childhood” Developmental Medicine & Child Neurlogy, vol. 47 (2005) pp. 4-9. |
Pathwardhan, R.V., et al., Control of Refractory status epilepticus precipitated by anticonvulasnt withdrawal using left vagal nerve stimulation: a case report, Surgical Neurology 64 (2005) 170-73. |
Poddubnaya, E.P., “Complex Estimation of Adaptation Abilities of the Organism in Children Using the Indices of Responsiveness of the Cardiovascular System and Characteristics of EEG” Neurophysiology vol. 38, No. 1 (2006); pp. 63-74. |
Rugg-Gunn, F.J., et al.; “Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219. |
Sajadieh, A., et al.; “Increased Heart Rate and Reduced Heart-Rte Variability are Associated with Subclinical Inflammation in Middle-Aged and Elderly Subjects with No Apparent Heart Disease” European Heart Journal vol. 25, (2004); pp. 363-370. |
Schernthaner, C., et al.; “Autonomic Epilepsy—The Influence of Epileptic Discharges on Heart Rate and Rhythm”The Middle European Journal of Medicine vol. 111, No. 10 (1999) pp. 392-401. |
Terry et al.; “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93. |
Tubbs, R.S., et al.; “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans” Child's Nervous System Original Paper; Springer-Verlag 2004. |
Umetani, M.D., et al.; “Twenty-Four Hour Time Domain Heart Rate Variability and Heart Rate: Relations to Age and Gender Over Nince Decades”JACC vol. 31, No. 3; (Mar. 1998); pp. 593-601. |
Vonck, K., et al. “The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401. |
Woodbury, et al., “Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating and Recording”; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107. |
Zabara, J.; “Neuroinhibition of Xylaine Induced Emesis” Pharmacology & Toxicology, vol. 63 (1988) pp. 70-74. |
Zabara, J. “Inhibition of Experimental Seizures in Canines by Repetivie Vagal Stimulation” Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012. |
Zabara, J., et al.; “Neural Control of Circulation I”The Physiologist, vol. 28 No. 4 (1985); 1 page. |
Zabara, J., et al.; “Neuroinhibition in the Regulation of Emesis” Space Life Sciences, vol. 3 (1972) pp. 282-292. |
Osorio, Ivan et al., “An Introduction to Contingent (Closed-Loop) Brain Electrical Stimulation For Seizure Blockage, To Ultra-Short-Term Clinical Trials, And To Multidimensional Statistical Analysis Of Therapeutic Efficacy,” Journal Of Clinical Neurophysiology, vol. 18, No. 6, pp. 533-544, 2001. |
Osorio, Ivan et al., “Automated Seizure Abatement In Humans Using Electrical Stimulation,” Annals Of Neurology, vol. 57, No. 2, pp. 258-268, 2005. |
Sunderam, Sridhar et al., “Vagal And Sciatic Nerve Stimulation Have Complex, Time-Dependent Effects On Chemically-Induced Seizures: A Controlled Study,” Brain Research, vol. 918, pp. 60-66, 2001. |
Weil, Sabine et al, “Heart Rate Increase In Otherwise Subclinical Seizures Is Different In Temporal Versus Extratemporal Seizure Onset: Support For Temporal Lobe Automatic Influence,” Epileptic Disord., vol. 7, No. 3, Sep. 2005, pp. 199-204. |
Digenarro, Giancarlo et al., “Ictal Heart Rate Increase Precedes EEG Discharge In Drug-Resistant Mesial Temporal Lobe Seizures,” Clinical Neurophysiology, No. 115, 2004, pp. 1169-1177. |
Zijlmans, Maeike et al., “Heart Rate Changes And ECG Abnormalities During Epileptic Seizures: Prevalence And Definition Of An Objective Clinical Sign,” Epilepsia, vol. 43, No. 8, 2002, pp. 847-854. |
O'Donovan, Cormac A. et al., “Computerized Seizure Detection Based On Heart Rate Changes,” abstract of AES Proceedings, Epilepsia, vol. 36, Suppl. 4, 1995, p. 7. |
Robinson, Stephen E et al., “Heart Rate Variability Changes As Predictor Of Response To Vagal Nerve Stimulation Therapy For Epilepsy,” abstract of AES Proceedings,Epilepsia, vol. 40, Suppl. 7, 1999, p. 147. |
Long, Teresa J. et al., “Effectiveness Of Heart Rate Seizure Detection Compared To EEG In An Epilepsy MoitoringUnit (EMU),” abstract of AES Proceedings, Epilepsia, vol. 40, Suppl. 7, 1999, p. 174. |
Number | Date | Country | |
---|---|---|---|
20120029390 A1 | Feb 2012 | US |